Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by 18F-FDOPA PET: Focus on missed lesions

Clinical Endocrinology

Volumn 79, Issue 2, 2013, Pages 170-177

  Gabriel, Sophie ^a   Blanchet, Elise M ^b   Sebag, Frédéric ^a   Chen, Clara C ^c   Fakhry, Nicolas ^a   Deveze, Arnaud ^d   Barlier, Anne ^d   Morange, Isabelle ^a   Pacak, Karel ^b   Taïeb, David ^a  

^a TIMONE HOSPITAL   (France)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODIHYDROXYPHENYLALANINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CAROTID BODY; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; FALSE NEGATIVE RESULT; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PET SCANNER; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR LOCALIZATION;

ABDOMINAL NEOPLASMS; ADRENAL GLAND NEOPLASMS; DIHYDROXYPHENYLALANINE; FALSE NEGATIVE REACTIONS; HEAD AND NECK NEOPLASMS; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE;

EID: 84880054080     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12126     Document Type: Article

References (25)

1. Timmers, H.J., Taieb, D., &, Pacak, K., (2012) Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 44, 367-372.
2. Taieb, D., Neumann, H., Rubello, D., et al,. (2012) Modern nuclear imaging for paragangliomas: beyond SPECT. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 53, 264-274.
3. Gimenez-Roqueplo, A.P., Favier, J., Rustin, P., et al,. (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer research 63, 5615-5621.
4. Amar, L., Baudin, E., Burnichon, N., et al,. (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. The Journal of clinical endocrinology and metabolism 92, 3822-3828.
5. Venkatesan, A.M., Trivedi, H., Adams, K.T., et al,. (2011) Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery 150, 1186-1193.
6. Timmers, H.J., Chen, C.C., Carrasquillo, J.A., et al,. (2012) Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. Journal of the National Cancer Institute 104, 700-708.
7. Fonte, J.S., Robles, J.F., Chen, C.C., et al,. (2012) False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-related cancer 19, 83-93.
8. Timmers, H.J., Chen, C.C., Carrasquillo, J.A., et al,. (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism 94, 4757-4767.
9. Timmers, H.J., Kozupa, A., Chen, C.C., et al,. (2007) Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Journal of Clinical Oncology 25, 2262-2269.
10. Luxen, A., Perlmutter, M., Bida, G.T., et al,. (1990) Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET. International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes 41, 275-281.
11. Taieb, D., Timmers, H.J., Hindie, E., et al,. (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 39, 1977-1995.
12. Lee, K.Y., Oh, Y.W., Noh, H.J., et al,. (2006) Extraadrenal paragangliomas of the body: imaging features. American Journal of Roentgenology 187, 492-504.
13. Treglia, G., Cocciolillo, F., de Waure, C., et al,. (2012) Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. European journal of nuclear medicine and molecular imaging 39, 1144-1153.
14. Rischke, H.C., Benz, M.R., Wild, D., et al,. (2012) Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 53, 1352-1358.
15. Hoegerle, S., Ghanem, N., Altehoefer, C., et al,. (2003) 18F-DOPA positron emission tomography for the detection of glomus tumours. European journal of nuclear medicine and molecular imaging 30, 689-694.
16. Taieb, D., Tessonnier, L., Sebag, F., et al,. (2008) The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clinical endocrinology 69, 580-586.
17. Fiebrich, H.B., Brouwers, A.H., Kerstens, M.N., et al,. (2009) 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. The Journal of clinical endocrinology and metabolism 94, 3922-3930.
18. Fottner, C., Helisch, A., Anlauf, M., et al,. (2010) 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. Journal of Clinical Endocrinology and Metabolism 95, 2800-2810.
19. Charrier, N., Deveze, A., Fakhry, N., et al,. (2011) Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: The case for a patient-tailored use of nuclear imaging modalities. Clinical endocrinology 74, 21-29.
20. King, K.S., Chen, C.C., Alexopoulos, D.K., et al,. (2011) Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D- glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. The Journal of clinical endocrinology and metabolism 96, 2779-2785.
21. Kruger, G.M., Mosher, J.T., Bixby, S., et al,. (2002) Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron 35, 657-669.
22. Cervera, A.M., Bayley, J.P., Devilee, P., et al,. (2009) Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Molecular cancer 8, 89.
23. Hentschel, M., Rottenburger, C., Boedeker, C.C., et al,. (2012) Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? Clinical nuclear medicine 37, e24-e29.
24. Timmers, H.J., Hadi, M., Carrasquillo, J.A., et al,. (2007) The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 48, 1599-1606.
25. Sandgren, J., Andersson, R., Rada-Iglesias, A., et al,. (2010) Integrative epigenomic and genomic analysis of malignant pheochromocytoma. Experimental & molecular medicine 42, 484-502.